Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: INTERCEPT Clear all
Completed No phase listed Observational

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

NCT07417618
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, ASCVD
Interventions
Dulaglutide, Semaglutide, Tirzepatide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60,000 participants
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial

NCT06664879
View directory record Official record
Conditions
AML
Interventions
MBG-453 + Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Not yet recruiting Phase 4 Interventional

Fibrinogen in Liver Transplant

NCT07265843
View directory record Official record
Conditions
Liver Transplant Surgery
Interventions
Intercept Fibrinogen Complex (IFC), Cryoprecipitate Antihemophilic Factor (AHF)
Biological
Lead sponsor
Trauma Hemostatis and Oxygenation Research (THOR) Network
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 8, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.

NCT06697223
View directory record Official record
Conditions
Healthy Subjects
Interventions
INTERCEPT Blood System for Platelets with LED Illuminator
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Norfolk, Virginia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Not yet recruiting No phase listed Observational

Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage

NCT07218185
View directory record Official record
Conditions
Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Interventions
Pathogen Reduced Cryoprecipitated Fibrinogen Complex
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Aurora, Colorado • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

NCT05711524
View directory record Official record
Conditions
Hypofibrinogenemia, Bleeding
Interventions
Traditional Cryoprecipitate, Pathogen-Reduced Cryoprecipitate
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 8, 2026, 10:10 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood Units

NCT03384407
View directory record Official record
Conditions
Red Cell Survival in Healthy Volunteers
Interventions
Red cell survival in INTERCEPT treated red cells
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 8, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

NCT06623110
View directory record Official record
Conditions
High-Risk Oral Precancerous Disease
Interventions
RP2 Injection
Biological
Lead sponsor
Glenn J. Hanna
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vending Labeling Sales and Intercepts Study

NCT06260176
View directory record Official record
Conditions
Food Preferences, Obesity, Weight Gain
Interventions
exposure to healthy labels only, exposure to healthiness information, exposure to physical activity equivalents, exposure to sweetened beverage tax messaging
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 8, 2026, 10:10 AM EDT
Terminated Phase 1 Interventional

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

NCT02295501
View directory record Official record
Conditions
Acute Ebola Virus Disease
Interventions
INTERCEPT Plasma
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 8, 2026, 10:10 AM EDT
Terminated Phase 1 Interventional

Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM

NCT03283631
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
EGFRvIII-CARs
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 8, 2026, 10:10 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

EXD-959 Orthodontic Brackets and EXD-961 Related Instruments Trial

NCT03606551
View directory record Official record
Conditions
Malocclusion
Interventions
EXD-959 Bracket System
Device
Lead sponsor
3M
Industry
Eligibility
11 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
5
States / cities
Culver City, California • Wellington, Florida • Northfield, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 8, 2026, 10:10 AM EDT
Withdrawn Phase 4 Interventional

Fibrinogen in Liver Transplant Subjects

NCT06764927
View directory record Official record
Conditions
Liver Transplant Surgery
Interventions
Cryoprecipitate Intercept Fibrinogen Complex (IFC), Cryoprecipitate Antihemophilic Factor (AHF)
Biological
Lead sponsor
Ezeldeen Abuelkasem
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

NCT02653443
View directory record Official record
Conditions
Healthy
Interventions
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets., Autologous apheresis Conventional untreated Platelet Components
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Lebanon, New Hampshire • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 8, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

NCT03459287
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT, Control
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
11 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 8, 2026, 10:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Test the AdaptDx Pro Agreement in Rod Intercept Time With the AdaptDx in Healthy Subjects With Normal Vision (FlashBack)

NCT07803588
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
AdaptDx Tabletop vs AdaptDx Pro
Diagnostic Test
Lead sponsor
AdaptDx, Inc.
Industry
Eligibility
22 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Recruiting Not applicable Interventional

Platform of Randomized Adaptive Clinical Trials in Critical Illness

NCT05440851
View directory record Official record
Conditions
Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions
Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
Other · Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Completed No phase listed Observational

A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components

NCT02549222
View directory record Official record
Conditions
Transfusion Related Acute Lung Injury
Interventions
Standard of Care
Other
Lead sponsor
Cerus Corporation
Industry
Eligibility
Not listed
Enrollment
2,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 8, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days

NCT04022889
View directory record Official record
Conditions
Healthy
Interventions
INTERCEPT Treated Platelets
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 8, 2026, 10:10 AM EDT
Not yet recruiting Phase 1 Interventional

Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors

NCT07224568
View directory record Official record
Conditions
Solid Tumor (Excluding CNS), Hepatocellular Carcinoma, Liver Cell Carcinoma, Liposarcoma, Yolk Sac Tumor, Rhabdomyosarcoma
Interventions
SC-CAR.GPC3xIL15.21 CAR T cells
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2045
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 8, 2026, 10:10 AM EDT
Active, not recruiting Phase 3 Interventional

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

NCT03037164
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
4 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 8, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

NCT07015437
View directory record Official record
Conditions
Healthy Subjects
Interventions
INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs
Device · Other
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 8, 2026, 10:10 AM EDT